Internal Medicine, Medical Oncology · The Woodlands, TX
NPI
1295798874
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
3
Medicare group memberships
Hospitals
5
Hospital affiliations
9303 Pinecroft Dr Ste 280
The Woodlands, TX, 77380
Phone (832) 813-5259
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.3M
277,321 services
Medicare patients, 2024
172
Average age 75
Drug cost, 2024
$5.9M
1,930 prescriptions
Company payments, 2025
$153
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Asit J Choksi was code Q5101 (injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram), 155,282 times for 20 patients. In total Asit J Choksi billed 277,321 services in 104 codes, and Medicare paid $2.3M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-02-13.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| Q5101 Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 155,282 | 20 | $0.22 | $34K |
| J9299 Injection, nivolumab, 1 mg | Office | 45,240 | 15 | $19.99 | $904K |
| J1756 Injection, iron sucrose, 1 mg | Office | 7,800 | 18 | $0.18 | $1,369 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 7,092 | 34 | $0.09 | $627 |
| J0897 Injection, denosumab, 1 mg | Office | 3,900 | 12 | $15.78 | $62K |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 3,017 | 35 | $0.26 | $778 |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2,240 | 11 | $6.38 | $14K |
| J7050 Infusion, normal saline solution, 250 cc | Office | 2,148 | 73 | $0.52 | $1,108 |
| 96367 Intravenous Infusion, Hydration | Office | 1,490 | 60 | $21.66 | $32K |
| 96372 Injection Administration | Office | 545 | 41 | $10.38 | $5,659 |
| 36415 Venipuncture Blood Collection | Office | 502 | 94 | $8.65 | $4,342 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 426 | 48 | $0.63 | $270 |
| 96413 Chemotherapy Administration | Office | 400 | 36 | $97.59 | $39K |
| 99213 Office E&M - Established | Office | 362 | 85 | $62.83 | $23K |
| J3490 Unclassified drugs | Office | 319 | 38 | $6.62 | $2,111 |
By year: 2022 $2.5M for 241,640 services; 2023 $3.5M for 447,225 services; 2024 $2.3M for 277,321 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 502 | 94 | $8.65 | $4,342 |
Medicare prescription drug claims, 2024
In 2024, the drug Asit J Choksi prescribed most often to Medicare patients was Opdivo (Nivolumab), with 114 prescriptions and refills. In total Asit J Choksi wrote 1,930 Medicare prescriptions that cost $5.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Opdivo Nivolumab | 114 | 115 | 13 | $1.3M |
| Zarxio Filgrastim-Sndz | 114 | 114 | 24 | $253K |
| Prednisone Generic | 80 | 80 | 20 | $325 |
| Zoledronic Acid Generic | 48 | 48 | 11 | $2,053 |
| Eligard Leuprolide Acetate | 48 | 62 | Under 11 | $25K |
| Hydrocortisone Generic | 46 | 46 | Under 11 | $1,950 |
| Anastrozole Generic | 44 | 88 | 15 | $569 |
| Omeprazole Generic | 44 | 78 | 15 | $417 |
| Potassium Chloride Generic | 41 | 46 | 14 | $379 |
| Abiraterone Acetate Generic | 41 | 41 | Under 11 | $95K |
| Leucovorin Calcium Generic | 38 | 38 | Under 11 | $3,923 |
| Carboplatin Generic | 36 | 36 | 15 | $1,547 |
| Yervoy Ipilimumab | 34 | 36 | Under 11 | $651K |
| Oxaliplatin Generic | 32 | 32 | Under 11 | $3,778 |
| Imfinzi Durvalumab | 31 | 31 | Under 11 | $379K |
Brand drugs: - claims; generic drugs: 1,126 claims; opioid claims: 76.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Asit J Choksi $153 ($153 in general payments such as food, travel and fees) from 5 companies. The largest payer was Eisai Inc. with $60.37.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.